Acasti Pharma (NASDAQ:ACST) Issues Earnings Results

Acasti Pharma (NASDAQ:ACSTGet Free Report) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.30, Yahoo Finance reports.

Acasti Pharma Trading Down 8.5 %

NASDAQ ACST opened at $3.02 on Monday. The firm has a market cap of $28.39 million, a price-to-earnings ratio of -0.65 and a beta of 1.61. The company has a 50 day moving average of $2.94 and a 200-day moving average of $2.91. Acasti Pharma has a 1-year low of $1.72 and a 1-year high of $3.84.

Acasti Pharma Company Profile

(Get Free Report)

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.

Read More

Earnings History for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.